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Abstract
Background: Neuropilin and tolloid-like 2 (NETO2) has been found to be overexpressed in different human cancers,
but its expression pattern and clinical relevance in colorectal carcinoma (CRC) remains unknown.
Methods: Real-time quantitative PCR, western blot and immunohistochemistry analyses were used to analyze the
expression of NETO2 in CRC clinical samples. The correlation of NETO2 expression with clinicopathologic features was
estimated in a cohort containing 292 patients with primary CRC. Kaplan-Meier and Cox proportional hazards regression
analyses were used to assess the prognostic value of NETO2 expression in CRC.
Results: The expression of NETO2 was frequently upregulated in CRC clinical samples at both the mRNA and protein
levels, and its upregulation was significantly correlated with poor tumor differentiation (p = 0.013), advanced local
invasion (p = 0.049), increased lymph node metastasis (p = 0.009), advanced TNM stage (p = 0.041) and increased
patient death (p = 0.001). Kaplan-Meier analysis of the complete study cohort revealed that patients with high-NETO2
tumors had a significantly shorter disease-specific survival (DSS) than those with low-NETO2 tumors (p < 0.001).
Importantly, high levels of NETO2 protein predicted poor DSS for patients with early stage tumors (p = 0.027) and for
those with advanced stage tumors (p = 0.020). Furthermore, multivariate analyses indicated that increased
NETO2 expression was an independent unfavorable prognostic factor for patients with early stage tumors
(hazard ratio [HR] = 1.937, 95 % CI = 1.107-3.390, p = 0.021) as well as patients with advanced stage tumors
(HR = 2.241, 95 % CI = 1.245-4.035, p = 0.007).
Conclusions: Our findings suggest that NETO2 upregulation could serve as a potential biomarker for the prediction of
advanced tumor progression and unfavorable prognosis in patients with CRC.
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Background
Colorectal carcinoma (CRC) is the third most commonly
diagnosed cancer in males and the second in females,
with an estimated 1.4 million cases and 693,900 deaths
occurring in 2012 [1]. Due to changes in dietary patterns
and risk factors of lifestyle, the incidence of CRC has
continued to increase in historically low-risk regions
including several countries in Eastern Europe and China
during the past decades [2–4]. The prognosis of CRC
patients has shown only limited improvement despite
advances in treatment approaches over the past few
years, and the 5-year relative survival has remained less
than 50 % in low-income countries [5, 6]. Currently,
stage at diagnosis is still the most important prognostic
indicator, and classification according to TNM stage
provides valuable prognostic information and guides
therapy decisions for CRC patients. However, clinical
outcome of CRC patients after surgical resection varies
greatly, even when patients are assigned to the same
TNM category [7, 8]. Consequently, there is an urgent
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need to identify novel biomarkers to improve prognosis
prediction for patients with CRC.
Neuropilin and tolloid-like 2 (NETO2), a single-pass
transmembrane protein and, along with its only paralog
NETO1, belongs to the unique subfamily of CUB domain-
and LDLa-containing proteins [9]. Up to now, most studies
have implicated the NETO2 gene in neuron-specific
processes. It has been identified that NETO2 and NETO1
proteins function as auxiliary subunits of neuronal kainate
receptors (KARs), which play important roles in excitatory
synaptic transmission in the vertebrate brain [10], and
modulate the kinetics of KARs by slowing desensitization
or accelerating recovery from desensitization for these
receptors [11, 12]. Therefore, it is proposed that NETO2,
as well as NETO1, may provide an alternative target for
the development of new drugs regulating KARs and brain
function [13]. Mechanistic investigations have revealed that
NETO2 could interact with the scaffolding protein
Glutamate receptor-interacting protein (GRIP) and regu-
late synaptic abundance of KARs [14]. In addition, NETO2
has been demonstrated to be a K+–Cl− cotransporter
(KCC2) interacting protein and required for neuronal Cl−
regulation in hippocampal neurons [15]. Although NETO2
was initially believed to be a brain-specific protein [9, 11], a
recent study conducted by Oparina et al. revealed that
NETO2 mRNA expression was also detectable in a variety
of normal non-neural tissues and upregulated in several
types of cancers including renal, lung, colon and cervical
carcinomas [16]. Moreover, they provided evidence that
the NETO2 mRNA level could be a potential marker for
early diagnosis in renal cancer and non-small cell lung
cancer. These new findings encourage further investigation
of its potential clinical significance in human malignancies.
Since the expression pattern and clinical relevance of
NETO2 has not been investigated in human CRC, in the
present study, we determined both the mRNA and pro-
tein expression levels of NETO2 in CRC clinical samples
and further analyzed the correlation of NETO2 expres-
sion with clinicopathologic features and with patient
survival based on tumor stage. Our results demonstrated
that increased expression of NETO2 was correlated with
tumor progression and might serve as an independent
unfavorable prognostic indicator for patients with CRC.
Methods
Patients and specimens
Formalin-fixed paraffin-embedded tissue specimens from
292 stages I–III CRC patients who received curative
surgery in our hospital (150th Hospital of the People's
Liberation Army (PLA), Luoyang, China) from July 2006
to December 2009 were retrieved for immunohistochem-
istry. The study cohort consisted of CRC patients with
typical adenocarcinoma histology as confirmed by patho-
logical analysis. Distribution of the continuous variables of
the study cohort was listed in Table 1. Detailed clinico-
pathologic characteristics of the patients were listed in
Table 2. The follow-up period was defined as the interval
from the date of surgery to the date of death or last
follow-up. The latest follow-up was updated in September
2014, and the median follow-up time of the study cohort
was 66 months (range, 1–98 months). Patients alive at the
end of follow-up were censored. Disease-specific survival
(DSS) was defined as the interval from the date of surgery
to the date that patient died from CRC-related causes.
Patients were excluded from the study cohort with the
following exclusion criteria: previously received any anti-
cancer therapy; impaired heart, lung, liver, or kidney func-
tion; previous malignant disease; died from diseases other
than CRC or from unexpected events. TNM staging was
classified according to the American Joint Committee on
Cancer staging manual (seventh edition). 5 fluoruracil-
based adjuvant chemotherapy was given to all stage III pa-
tients and a subgroup of stage II patients who had at least
one of the following risk factors: pT4, bowel obstruction
or perforation, poorly differentiated tumors, or less than
12 lymph nodes discovered after surgery.
A set of 57 paired fresh-frozen CRC samples obtained
from stages I–III primary CRC patients who received
curative surgery in our hospital from April 2013 to June
2013 were used for quantitative polymerase chain reac-
tion (qPCR) analysis. An independent set of 24 paired
fresh-frozen CRC samples obtained from stages I-III
CRC patients who received curative surgery in our
hospital from July 2013 to August 2013 were used for
Western blot analysis. Written informed consent was
obtained from each patient and this study was approved
by the institutional Ethics Committee of our hospital.
Real-time qPCR analysis
Real-time qPCR analysis was performed as described pre-
viously [17]. Briefly, total RNAs were isolated from frozen
specimens using TRIzol Reagent (Ambion, 80706, USA).
Reverse transcription was performed using RevertAidTM
First Strand cDNA Synthesis Kit (Thermo Scientific,
K1622, Lithuania) according to the manufacturer’s
instructions. qPCR was performed on ABI Prism 7500
Sequence Detection System with SYBR Premix Ex Taq™ II
Table 1 Distribution of continuous variables of the study cohort
(n = 292)




Age (years) 66.0 65.5 ± 0.7 30.0-96.0 58.0 74.0
Tumor size (cm) 5.0 5.4 ± 0.2 1.5-15.0 4.0 6.0
Follow-up time (months) 66.0 56.3 ± 1.6 1.0-98.0 31.0 77.0
DSS time (months) 26.0 28.6 ± 1.7 1.0-80.0 13.0 42.0
Abbreviations: SEM, Standard error of the mean; DSS, Disease-specific survival
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(Takara, RR820A, Japan) using the 2-ΔΔCT method. Gene
expression results were normalized by internal control β-
actin. The primers used in this study are as follows:
NETO2 (NM_001201477.1) forward, 5'-AGCTGCTCCA
CGTCAAAGAA-3'; reverse, 5'- GCTCCCGAGAGCTC
GAA-3'; β-actin forward, 5'-AATCGTGCGTGACATTAA
GGAG-3'; reverse, 5’-ACTGTGTTGGCGTACAGGTCT
T-3'. Each sample was tested in triplicate.
Western blot analysis
Western blotting was performed as described previously
[18]. Briefly, tumor specimens were prepared in lysis
buffer [Tris–HCl (20 mM), pH 7.4, NaCl (150 mM),
glycerol (10 %), Nonidet P-40 (0.2 %), EDTA (1 mM),
EGTA (1 mM), PMSF (1 mM), NaF (10 mM), aprotinin
(5 mg/ml), leupeptin (20 mM), and sodium orthovana-
date (1 mM)] and centrifuged at 12,000 g for 30 min.
Protein concentrations were measured using the BCA
assay. Immunoblotting was performed using a primary
antibody specific for NETO2 (Abcam, ab109288) and
immunocomplexes were incubated with goat anti-rabbit
fluorescein-conjugated secondary antibodies, and then
detected using an Odyssey fluorescence scanner (Li-Cor,
Gene Company). β-actin was used as a loading control
(Santa Cruz Biotechnology, sc-47778).
Immunohistochemistry and immunocytochemistry
Immunohistochemistry of paraffin-embedded tissue
sections was performed as described previously [19].
Briefly, sections were deparaffinized and rehydrated. The
endogenous peroxidase activity was blocked with 3 %
H2O2 for 10 min. Antigens were retrieved with citrate
buffer (10 mM, pH 6.0) for 15 min at 100 °C in a micro-
wave oven. After blocking, the sections were incubated
with a primary anti-NETO2 antibody (Abcam, ab171651)
with 1:200 dilution at 4 °C overnight in a moist chamber
followed by incubated with an anti-rabbit peroxidase-
conjugated secondary antibody (Santa Cruz) at room
temperature for 30 min. Finally, the visualization signal
was developed with diaminobenzidine (Dako) and the
slides were counterstained with hematoxylin. Immuno-
cytochemistry was performed using human CRC cell line
HCT15 as a positive control for immunostaining of
NETO2 and HCT116 as a negative control.
Stained sections were evaluated in a blinded manner
without prior knowledge of the clinical data using the
German immunoreactive score (IRS) as described previ-
ously [20]. Briefly, staining intensity was graded as “0”
(negative), “1” (weak), “2” (moderate) and “3” (strong);
staining extent was graded as “0” (<5 %), “1” (5–25 %),
“2” (25–50 %), “3” (50–75 %) or “4” (>75 %). Values of
the staining intensity and the staining extent were multi-
plied as a final IRS of NETO2 expression. Using this
method of assessment, we evaluated NETO2 expression
Table 2 Association between NETO2 expression and




Low (%) High (%) P value a
(n = 292) (n = 115) (n = 177)
Age (years) 0.864
<60 88 (30.1) 34 (29.6) 54 (30.5)
≥60 204 (69.9) 81 (70.4) 123 (69.5)
Sex 0.860
Female 111 (38.0) 43 (37.4) 68 (38.4)
Male 181 (62.0) 72 (62.6) 109 (61.6)
Tumor location 0.227
Right colon 88 (30.1) 31 (27.0) 37 (20.9)
Left colon 71 (24.4) 34 (29.5) 57 (32.2)
Rectum 133 (45.5) 50 (43.5) 83 (46.9)
Differentiation grade 0.013
Well 20 (6.8) 12 (10.4) 8 (4.5)
Moderate 222 (76.0) 91 (79.2) 131 (74.0)
Poor 50 (17.2) 12 (10.4) 38 (21.5)
Tumor size (cm) 0.446
<5 114 (39.0) 48 (41.7) 66 (37.3)
≥5 178 (61.0) 67 (58.3) 111 (62.7)
Local invasion 0.049
T1-T2 48 (16.4) 25 (21.7) 23 (13.0)
T3-T4 244 (83.6) 90 (78.3) 154 (87.0)
Lymph node metastasis 0.009
N0 164 (56.2) 74 (64.3) 90 (50.8)
N1 101 (34.6) 37 (32.2) 64 (36.2)
N2 27 (9.2) 4 (3.5) 23 (13.0)
TNM stage 0.041
I 40 (13.7) 21 (18.3) 19 (10.7)
II 124 (42.5) 53 (46.1) 71 (40.1)
III 128 (43.8) 41 (35.6) 87 (49.2)
No. of examined lymph nodes 0.655
<12 152 (52.1) 58 (50.4) 94 (53.1)
≥12 140 (47.9) 57 (49.6) 83 (46.9)
Bowel obstruction/perforation 0.537
No 282 (96.6) 112 (97.4) 170 (96.0)
Yes 10 (3.4) 3 (2.6) 7 (4.0)
Adjuvant chemotherapy 0.060
No 98 (33.6) 46 (40.0) 52 (29.4)
Yes 194 (66.4) 69 (60.0) 125 (70.6)
Death 0.001
No 168 (57.5) 80 (69.6) 88 (49.7)
Yes 124 (42.5) 35 (30.4) 89 (50.3)
aPearson chi-square test or Fisher exact test was used for comparison between
subgroups. Bold type indicates statistical significance
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in CRC tissues by the IRS of 0, 1, 2, 3, 4, 6, 8, 9, or 12.
The median value of the IRS was chosen as the cut-off
for high and low NETO2 expression levels based on a
measure of heterogeneity according to the log-rank test
with respect to DSS, as described previously [21]. An
IRS of ≥ 6 was used to indicate tumors with high NETO2
expression and an IRS of < 6 was used to define tumors
with low NETO2 expression. Discrepancies in the IRS
were resolved by discussing together with other patholo-
gists to reach a consensus.
Statistical analysis
Pearson chi-square test or Fisher exact test was used to
analyze the relationship between NETO2 expression and
clinical features. Kaplan-Meier analysis with log-rank
test was used to compare patients’ survival between sub-
groups. The effect of each variable on survival was deter-
mined by the Cox multivariate regression analysis. All
statistical analyses were carried out using SPSS PASW
Statistics 18.0 software (SPSS, Inc., Chicago, IL), and p
value < 0.05 was considered to be statistically significant.
Results
Overexpression of NETO2 in primary CRC tissues
The expression levels of NETO2 mRNA in 57 paired CRC
and corresponding adjacent normal mucosa specimens
were quantified by real-time qPCR method. The results
showed that NETO2 mRNA expression was significantly
upregulated in the cancerous tissues compared with adja-
cent normal counterparts, in which 52.6 % (30/57) of the
cancerous specimens tested showed a significant increase
(over 2-fold) in NETO2 mRNA level (Fig. 1a, p < 0.01). To
determine the protein levels of NETO2 in CRC, an inde-
pendent set of 24 paired CRC and corresponding adjacent
normal mucosa specimens were subjected to Western blot
assay. As shown in Fig. 1b, the protein levels of NETO2
were also significantly higher in cancerous tissues than in
adjacent normal counterparts (p < 0.001).
To further evaluate the phenotypic expression of
NETO2 protein in CRC clinical samples, immunohisto-
chemical analysis was performed in another independent
set of 292 pairs of CRC specimens and adjacent normal
tissues. The immunoreactivity of NETO2 protein was ob-
served primarily in the cytoplasm. The staining intensities
were classified into four levels: level 1 with negative stain-
ing, level 2 with weak staining, level 3 with moderate
staining, and level 4 with strong staining (Fig. 2a). Overall,
9.2 % (27/292) of the cancerous specimens showed strong
staining, 67.5 % (197/292) of the cases showed moderate
staining, 18.2 % (53/292) of the cases showed weak stain-
ing, and only 5.1 % (15/292) of the cases showed negative
staining of NETO2 protein. In striking contrast, 34.9 %
(102/292) of the adjacent normal mucosa tissues showed
negative staining, 40.8 % (119/292) of the cases showed
weak staining, 22.9 % (67/292) of cases showed moderate
staining, and only 1.4 % (4/292) of cases showed strong
staining of NETO2 (Fig. 2b, p < 0.001). Thus, NETO2 was
frequently overexpressed in primary CRC tissues.
Correlation of NETO2 expression with clinicopathologic
features
To evaluate the association between NETO2 expression
levels and clinicopathologic characteristics, the 292
patients were classified into high and low NETO2
expression subgroups with the median IRS value as the
cut-off. As shown in Table 2, high expression of
NETO2 protein was significantly correlated with poor
tumor differentiation (p = 0.013), advanced local invasion
(p = 0.049), increased lymph node metastasis (p = 0.009),
advanced TNM stage of the disease (p = 0.041), and in-
creased death rate of patients (p = 0.001). While, there
were no significant associations between NEOT2 expres-
sion and patient age (p = 0.864), sex (p = 0.860), tumor
location (p = 0.227), tumor size (p = 0.446), number of
examined lymph nodes (p = 0.655), preoperative bowel
obstruction or perforation (p = 0.537), or adjuvant chemo-
therapy (p = 0.060).
Prognostic values of NETO2 expression for patients with CRC
Of the 292 patients, 124 had died from disease progres-
sion within the follow-up period. The cumulative 5-year
disease-specific survival (DSS) rate was 60.3 %. Kaplan-
Meier analysis of the complete study cohort revealed that
patients with high-NETO2 tumors had a significantly
shorter DSS than those with low-NETO2 tumors (Fig. 3a,
p < 0.001). The cumulative 5-year DSS rate was 71.3 % in
patients with low-NETO2 tumors, whereas it was only
53.1 % in those with high-NETO2 tumors. In our cohort,
patients who had advanced stage (stage III) tumors
had a significantly unfavorable prognosis compared
with those who had early stage (stages I-II) tumors
(Fig. 3b, p < 0.001).
Survival analyses based on tumor stage (early and
advanced) demonstrated that high expression of NETO2
significantly predicted poor DSS in patients with early
stage tumors (Fig. 3c, p = 0.027). Similarly, high levels of
NETO2 also significantly predicted poor DSS in patients
with advanced stage tumors (Fig. 3d, p = 0.020).
To assess whether NETO2 expression represents an
independent prognostic indicator in CRC, the effect of
each variable on survival was determined by the Cox
regression analysis. Univariate analyses revealed that
NETO2 expression (HR = 1.986, 95 % CI = 1.343-2.937,
p = 0.001), TNM stage (HR = 1.832, 95 % CI = 1.286-2.609,
p = 0.001), tumor differentiation grade (HR = 1.691, 95 %
CI = 1.103-2.591, p = 0.016), and patient age (HR = 1.674,
95 % CI = 1.098-2.551, p = 0.017) were significantly associ-
ated with DSS (Table 3). The variables that significantly
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correlated with survival in the univariate analysis were
further assessed by multivariate analysis. The results of
the multivariate analysis confirmed that NETO2 expres-
sion (HR = 1.924, 95 % CI = 1.300-2.848, p = 0.001), TNM
stage (HR = 1.878, 95 % CI = 1.313-2.685, p = 0.001), and
patient age (HR = 1.875, 95 % CI = 1.225- 2.871, p = 0.004)
were independent prognostic factors for patients with
CRC (Table 3).
The independent prognostic significance of NETO2
expression on CRC-specific survival based on tumor stage
was further evaluated with a Cox regression model. The
results showed that increased NETO2 expression was an
independent indicator of a poor prognosis for patients
with early stage tumors (HR = 1.937, 95 % CI = 1.107-
3.390, p = 0.021) as well as for those with advanced stage
tumors (HR = 2.241, 95 % CI = 1.245-4.035, p = 0.007). For
patients with advanced stage tumors, age (HR = 2.229;
95 % CI = 1.264-3.932, p = 0.006) and number of ex-
amined lymph nodes (HR = 0.584; 95 % CI = 0.351-
0.973, p = 0.039) were also significantly associated
with patient survival (Table 4).
Discussion
NETO2 was initially reported to be specifically expressed
in the nervous system and previous investigations of this
gene focused almost entirely on the neurobiological
aspects, but subsequent studies revealed that it is
dysregulated in several pathological conditions. Using
a genome-wide transcriptional profiling analysis, Calicchio
et al. reported that NETO2 belongs to the genes overex-
pressed in proliferating hemangiomas relative to normal
placental vessels [22]. In addition, Horak et al. found that
Fig. 1 Expression of NETO2 in primary CRC tissues. a NETO2 mRNA expression in 57 paired human CRC and corresponding adjacent normal mucosa
specimens were determined by real-time qPCR method. Gene expression results were normalized by internal control β-actin. (T, tumor tissues; N,
adjacent normal tissues). b Protein expression levels of NETO2 in an independent set of 24 paired CRC and corresponding adjacent normal specimens
were determined by Western blot analysis. β-actin was used as a loading control. The relative protein expression of NETO2 was quantified
and normalized to β-actin. Each N was arbitrarily designated 1.0. (T: Tumor tissues; N: adjacent normal tissues, T vs N, p < 0.001)
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it could be downregulated by the metastasis suppressor
gene Nm23-H1 in breast carcinoma cell lines [23].
Notably, Oparina et al. recently demonstrated that the
NETO2 mRNA is frequently overexpressed in a number
of human neoplasms and might be a tool to support the
early diagnosis of renal and lung carcinomas [16]. These
findings indicate that NETO2 may have potential sig-
nificance in cancer pathobiology. Nevertheless, the
clinical relavance of NETO2 expression has not been
assessed in CRC.
The present study, to our knowledge, is the first to
report the phenotypic expression pattern of NETO2 and
its clinical significance in CRC. Using real-time qPCR
and Western blot analysis, we found that NETO2 was
frequently overexpressed in primary CRC samples at
both the mRNA and protein levels. Our results are
consistent with the previous findings of Oparina et al. at
the mRNA level [16]. Of note, we observed a significant
increase in NETO2 mRNA level (over 2-fold) in 52.6 %
(30/57) of the cancerous specimens tested, whereas
Oparina et al. reported that only 40 % (4/10) of colon
cancer samples showed substantially increased expression
of NETO2 mRNA. This discrepancy may result from
the difference in the sample size, ethnic group or
endogenous control gene used for normalization.
Notably, as these tumor tissues were not isolated by
laser capture microdissection technology, the inclu-
sion of non-epithelial cells not expressing NETO2 in
Fig. 2 Immunostaining of NETO2 protein in human CRC and adjacent normal tissues. a Representative immunohistochemical expression patterns
of NETO2 in cancerous and adjacent normal mucosa specimens were shown. (Magnification, upper panel, ×100; lower panel, ×400) Right panel:
human CRC cell line HCT116 cells were used as a negative control and HCT15 cells were used as a positive control for immunostaining of NETO2
protein. (Magnification × 100) (b) Percentage of cases with different staining intensity of NETO2 in the tumor or adjacent normal tissues in the
study cohort. (p < 0.001)
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Fig. 3 Kaplan-Meier survival analysis for CRC patients. a Kaplan-Meier curves for disease-specific survival of all CRC patients in the study cohort
according to NEOT2 expression status. b Kaplan-Meier curves for disease-specific survival of all CRC patients according to TNM stage. c-d Kaplan-Meier
curves for disease-specific survival of patients with early stage tumors (c) or advanced stage tumors (d) according to NETO2 expression
status. The p-value was determined using the log-rank test. The absolute number of patients at risk in each subgroup is listed below
Table 3 Univariate and multivariate analyses of prognostic factors for disease-specific survival of CRC patients in the study cohort
Variables Categories Univariate analysis Multivariate analysis
HR 95 % CI P valuea HR 95 % CI P valuea
Age (years) ≥60/<60 1.674 1.098-2.551 0.017 1.875 1.225-2.871 0.004
Sex Male/female 1.141 0.791-1.646 0.480
Tumor location Colon/rectum 0.960 0.674-1.367 0.820
Tumor size (cm) ≥5/<5 1.161 0.807-1.672 0.421
No. of examined lymph nodes ≥12/< 12 0.952 0.669-1.354 0.783
Bowel obstruction/perforation Yes/no 0.962 0.355-2.607 0.940
Adjuvant chemotherapy Yes/no 1.246 0.851-1.825 0.259
Differentiation grade Poor well + moderate 1.691 1.103-2.591 0.016
TNM stage III/I+ II 1.832 1.286-2.609 0.001 1.878 1.313-2.685 0.001
NETO2 expression High/low 1.986 1.343-2.937 0.001 1.924 1.300-2.848 0.001
Abbreviations: HR, hazard ratio; 95 % CI, 95 % confidence interval
aBold type indicates statistical significance
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PCR and Western blot experiments may interfere
with the evaluation of NETO2 expression in CRC and
adjacent normal tissues. Nevertheless, our subsequent
immunohistochemical analysis of 292 paired CRC
specimens demonstrated that expression of NETO2
protein was significantly upregulated in the cancerous
colorectal epithelial cells compared with the adjacent
normal counterparts, in which 76.7 % (224/292) of the
cancerous tissues presented moderate-strong staining of
NETO2 protein, whereas only 24.3 % (71/292) of the adja-
cent normal tissues showed virtually the same immunore-
activity. Thus, our results unambiguously confirmed the
significant upregulation of NETO2 expression in CRC. In
addition, unlike the reported transmembrane localization
in neurons [9, 11], we found that NETO2 protein was
mainly localized in the cytoplasm. This observation is in
agreement with the results of the Protein Atlas large-scale
immunohistochemical study of human proteins, which
displayed a cytoplasmic staining of NETO2 in human
normal colorectal tissues [http://www.proteinatlas.org/
ENSG00000171208]. Hence, although NETO2 gene was
initially found only expressed in brain of human and mice
by Northern blotting and in situ hybridization analysis [9],
the data collected from Oparina et al. and our group dem-
onstrated that it is also expressed in non-neural normal
and neoplastic tissues. Moreover, the observed significant
upregulation of NETO2 expression in malignant diseases
is in accordance with similar cases where expression of
certain neuron-specific proteins is activated in oncogen-
esis [24, 25]. However, the molecular basis and biological
relevance of NETO2 overexpression in CRC is currently
unclear and needs further investigation.
Interestingly, according to our results, increased expres-
sion of NETO2 protein in CRC was significantly correlated
with poor differentiation, advanced local invasion, in-
creased lymph node metastasis and advanced TNM stage,
indicating that NETO2 may be involved in the pro-
gression of CRC. It should be noted that, although
our data demonstrated an association of NETO2
expression with aggressive clinical phenotypes,
whether NETO2 plays a functional role in the pro-
gression of CRC needs to be carefully determined.
Since the increase in NETO2 expression could also
be the result of other factors that lead to cancer pro-
gression, rather than NETO2 overexpression being a
contributing factor in cancer progression. Further in
vitro and in vivo functional studies are warranted to
address this issue.
The most important finding of the present study was
the prognostic value of NETO2 in CRC patients. We
observed a significant association between increased
NETO2 protein expression and poor survival of CRC
patients in both univariate and multivariate survival
analyses. In addition, our results also demonstrated that
TNM stage is an important prognostic factor in CRC,
which is consistent with the well established adverse
prognostic effect of tumor stage [26] and confirms that
our cohort was representative and that the survival ana-
lyses were valid. Moreover, stage-based survival analyses
revealed that increased expression of NETO2 protein in
tumors not only significantly predicted poor DSS but
also was an independent unfavorable prognostic indica-
tor for patients with early stage tumors as well as for
those with advanced stage tumors. These findings should
be of particular interest especially for patients who have
early stage tumors. It is well known that TNM staging
has a great influence on CRC prognosis and is clinically
accepted as a solid basis for therapeutic management.
However, dilemmas are often raised with respect to the
treatment of patients with early stage disease. Generally
speaking, patients who had early stage CRCs have a
favorable prognosis compared with those who had
Table 4 Multivariate analyses of prognostic factors for disease-specific survival of patients with early or advanced stage tumors in
the study cohort
Variables Categories Early stage Advanced stage
HR 95 % CI P valueb HR 95 % CI P valueb
Age (years) ≥60/<60 1.705 0.860-3.381 0.127 2.229 1.264-3.932 0.006
Sex Male/female 0.818 0.462-1.447 0.489 1.575 0.934-2.658 0.089
Tumor location Colon/rectum 1.095 0.802-1.495 0.569 0.968 0.727-1.290 0.826
Tumor size (cm) ≥5/<5 0.920 0.536-1.579 0.762 1.558 0.915-2.652 0.103
No. of examined lymph nodes ≥12/< 12 1.525 0.785-2.964 0.213 0.584 0.351-0.973 0.039
Bowel obstruction/perforation Yes/no 1.365 0.175-10.672 0.767 0.689 0.209-2.269 0.541
Adjuvant chemotherapya Yes/no 0.808 0.397-1.644 0.556
Differentiation grade Poor/well + moderate 0.690 0.207-2.298 0.545 1.591 0.946-2.678 0.080
NETO2 expression High/low 1.937 1.107-3.390 0.021 2.241 1.245-4.035 0.007
Abbreviations: HR, hazard ratio; 95 % CI, 95 % confidence interval
aAs all advanced stage patients had received adjuvant chemotherapy, adjuvant chemotherapy was not enrolled into the multivariate analysis
bBold type indicates statistical significance
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advanced stage CRCs. Nevertheless, a subgroup of
patients with early stage disease have an increased risk
of early recurrence and death [27]. Hence, it is of
particular importance to identify this high-risk subgroup
of patients for appropriate treatment. Thus, results from
the present work suggest that NETO2 expression status
could serve as a promising biomarker to classify patients
with early stage tumors into distinct risk subgroups and
guide individualized therapeutic strategy.
The present study had several limitations. Although
our results revealed the clinicopathologic correlation
and prognostic value of NETO2 protein expression in a
cohort of CRC patients, the potential role of NETO2 in
the development of CRC has not been elucidated. In
addition, due to the limitation of follow-up period, the
median survival time of patients with low-NETO2
tumors could not be obtained, thus, our current results
could not accurately reflect the survival of patients in
this subgroup. Besides, since the limited quantity of
CRC tissue samples, three independent sets of CRC
specimens were used with each set studied with each of
the method (qPCR, Western, IHC). Therefore, the fact
that different sets were employed makes impossible any
direct comparison to specifically answer the question of
whether there is a correlation between NETO2 expres-
sion in the mRNA and protein levels. Further studies
are necessary to confirm our findings and clarify the
function and mechanism of NETO2 in the development
of CRC.
Conclusions
We here provide evidence, for the first time, that NETO2
expression was frequently upregulated in CRC tissues at
both the mRNA and protein levels. In addition, increased
expression of NETO2 was significantly associated with
disease progression and poor postoperative outcome of
CRC patients. Our results suggest that NETO2 might
serve as a novel prognostic molecular marker for patients
with CRC and encourage further investigation of its
potential role in CRC pathobiology.
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